Clinical operations
What Insmed’s TPIP extension study brings to Phase 3 in PAH
Explore Novo Nordisk’s Q3 2026 GLP-1 growth, CagriSema trial results, and implications for clinical operations, patient access and evidence quality.
By Lampgen Clinical Research
1 min read · estimated
What the source reported
Insmed reported sustained improvements in six-minute walk distance and NT-proBNP at 12 months in an open-label extension of investigational once-daily inhaled TPIP for pulmonary arterial hypertension. The extension followed participants from earlier studies without a concurrent placebo group.
What this means for trial teams
The extension adds longer-term observations on tolerability and functional outcomes. The randomized Phase 3 PALM-PAH study evaluates efficacy against placebo. Consistent walk-test administration, inhaler training, and tracking missed visits will help sites collect interpretable data across centers.